The problem of treatment of nonspecific inflammatory diseases of soft tissues of maxillofacial region, in particular inflammatory infiltrates, is one of the most urgent in surgical dentistry and maxillofacial surgery.
Conclusions: Based on Movixicam® ODT use in patients with inflammatory infiltrates of soft tissues of maxillofacial region and neck, the high analgesic and anti-inflammatory efficacy of it was significantly higher than that of traditional therapy, and also has had fewer complications associated with side effects. It was found that medicine Movixicam® ODT, having an anti-inflammatory effect on patients, promotes an increase in local and general nonspecific resistance of the organism. The use of this medicine allows reducing a number of purulent-inflammatory complications and to reduce the duration of ongoing treatment of patients.
It has been established that Movixicam® ODT is an effective analgesic and anti-inflammatory remedy and can be recommended for the treatment of patients with inflammatory infiltrates of soft tissues of maxillofacial region and neck, and also in order to prevent the development of purulent-inflammatory complications.